TumorGen is a drug discovery company focused on developing innovative therapies to combat cancer metastasis. Utilizing their patented technology, TumorGen captures circulating metastatic cancer cell clusters (MCCCs) to identify novel therapeutic targets. Their mission is to stop the metastatic spread of cancer, which is often the most deadly aspect of the disease. TumorGen aims to create new treatments that can save lives by targeting these rare and dangerous cell clusters.
Founded by individuals personally affected by cancer, including Jeff Allen, who lost his wife to the disease, TumorGen is driven by a deep commitment to finding a cure. The company has made significant strides in the field of oncology with its unique approach to drug discovery. Their work has the potential to revolutionize cancer treatment by addressing the critical challenge of metastasis, offering hope to countless patients and families worldwide.
